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1. Introduction
Sjögren’s syndrome (SjS) is a chronic, inflammatory autoimmune disorder characterized by
dry mouth and dry eyes, in which lymphocytic infiltration (primarily CD4 T-cells) of the
salivary and lacrimal glands destroy their secretion abilities. Since abnormal activation of T-
cells are a key feature of SjS, as well as for other autoimmune conditions, defining the proc‐
esses for T-cell activation and inhibition are important for understanding SjS autoimmune
pathogenesis.
The molecules CD80 (B7.1) and CD86 (B7.2), here forth collectively referred to as B7, are crit‐
ical costimulatory ligands during the process of antigen presentation because of their abili‐
ties to support T-cell receptor (TCR)-mediated responses through their binding to and
activation of CD28 receptors on T-cells. Binding of either of these B7 ligands to cytotoxic T-
Lymphocyte Antigen 4 (CTLA-4, CD152) counter receptor are crucial for attenuating T-cell
responses. Additionally, these processes of activation and inhibition have been shown to be
modulated in part by regulatory T (Treg) cells, which are a naturally occurring cell popula‐
tion capable of directly suppressing effector T (Teff) cells activation and proliferation, espe‐
cially to self-antigens.
In autoimmune diseases, dysfunction of Treg cells is a potential contributor to disease devel‐
opment, where costimulatory requirements for Treg cell proliferation and suppression capa‐
bilities may not be met. It is possible that the relative contribution of CD86/CD80 and CD28/
CTLA-4 signals to Treg and Teff cells could dictate the potency of suppression and pheno‐
types of cells. This is important in understanding autoimmune diseases where abnormal ex‐
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pression of CD86 and CD80 is seen in the target tissue sites and dysregulation of specific
Treg populations may contribute to development of autoimmune disorders.
Elucidating biological function and mechanisms of action of the CD86/CD80:CD28/CTLA-4
molecules have been the focus of much research over the past several decades since their
seminal discoveries in the early 1990s. However, there are still many questions as to how
these molecules interact to form specific immune responses in vivo, especially in the field of
autoimmunity. In this book chapter, we will describe potential processes for T-cell activation
and inhibition and investigate the contribution of abnormal costimulatory/inhibitory signals
from CD80/CD86 to the establishment of autoimmune disorders, such as SjS.
2. Overview of costimulatory molecules for T-cell activation and
inhibition
Much of the difficulties in achieving a cohesive understanding of the CD86/CD80:CD28/
CTLA-4 system stem from various complexities, such as, cell type-specific expression (in‐
cluding varying protein levels and kinetics of expression) and assorted ligand:receptor inter‐
actions that contribute to the overall immune phenotype. In this section, we will focus on
the expression, interactions, and overall function of these receptors and ligands, especially
related to Treg cell activation and suppression function.
2.1. Expression of CD86/CD80:CD28/CTLA-4
The CD28 and CTLA-4 receptors are members of the CD28 family of immunoglobulin-like
glycoproteins that are genetically linked on human chromosome 2 and mouse chromosome
1, although they each have distinct patterns of cell surface expression. CD28 is well known
to be constitutively present at the surface of all T-cells (CD4 and CD8), where its surface lev‐
els are further increased to maximal by 24 hours following TCR activation. CTLA-4 on the
other hand is found predominantly located in intracellular vesicles. CTLA-4 is well known
to be rapidly removed from the cell surface by clatherin adaptor complex AP-2-mediated en‐
docytosis, such that only a small fraction of CTLA-4 is present on the cell surface under
steady-state conditions [1-5]. Following TCR activation CTLA-4 still retains its endocytosis
capabilities [6] and yet, its surface concentration is quickly increased by 48 hours after T-cell
activation. Delivery of CTLA-4 receptor to the immune synapse has also been shown to be
associated with the strength of TCR signaling [7]; indicating that T-cells with higher affinity
TCRs are potentially more likely to be attenuated by CTLA-4 receptor activation.
The two known CD28 and CTLA-4 ligands, CD86 and CD80, are members of the B7 family
of immunoglobulin-like proteins expressed on a variety of antigen presenting cell (APC)
types including dendritic cells (DCs), macrophages, and B-cells [8, 9]. Similar to the CD28
family, the B7 family of ligands appears to derive from gene duplication events, where they
are genetically linked on human chromosome 3 and mouse chromosome 16, although, they
too have very distinct patterns of expression from each other. CD86 is most commonly con‐
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stitutively expressed on the surface of professional antigen presenting cells (APCs) or cells
such as monocytes [8-10]. On these cell types CD86 is generally more abundantly expressed
than CD80. CD86 is rapidly upregulated and maximally expressed by 48 hours in response
to its interaction with CD28 receptor or other inflammatory stimuli [9, 11, 12]. Typically,
CD80 is not constitutively present on unactivated cells. Following initiation of CD28 or in‐
flammatory stimulation the expression of CD80 is produced at a much slower rate [9]. Inter‐
estingly, immature DCs (and Langerhans cells) show evidence that CD80 is the
predominantly expressed ligand compared to CD86 [13-15]. These findings are indicative of
a predominant role for CD80 in immature or regulatory cells [16-18].
2.2. Relative interaction properties of CD86/CD80:CD28/CTLA-4
The CD28/CTLA-4 receptors and the CD86/CD80 ligands function as multi-subunit proteins
comprising of identical protein subunits that provide unique ligand:receptor interactions.
CD28 is well known as a homodimer. However, this homodimer configuration only possess‐
es a single ligand binding site, in stark contrast to CTLA-4 homodimer, which is shown to
possess two ligand binding sites [19, 20]. Regarding the ligands themselves, CD80 exists as a
weak noncovalently bound homodimer based on analytical ultracentrifugation and crystal
structure of CD80 [21]. This same dimeric conformation was also observed following crystal‐
lization of CD80 complexed with CTLA-4 [20, 21] and photo-bleaching FRET confirmed that
CD80 exists predominantly as a dimer on the surface of APCs [22]. On the other hand, CD86
primarily exists as a monomer as detected by analytical ultracentrifugation and gel filtration
studies [23]. The crystal structure analysis of CD86 also revealed poor dimer interface [21],
but interestingly, crystallization of CD86 complex with CTLA-4 indicates that it can poten‐
tially form a dimer as well as crosslink CTLA-4 receptors [24]. Again, crystallization of CD86
without CTLA-4 or in solution indicates that CD86 is unlikely to form stable dimers [19, 23].
Findings based on photo-bleaching FRET also confirmed that CD86 exists as a monomer on
the cell surface [22], where CD86 tends to have a faster association and dissociation rate than
CD80 to either receptors [25]. The issue for potential receptor mediated dimerization of
CD86 is currently unresolved. These findings altogether suggest that CD28 is restricted to
having one ligand binding partner, whereas, CTLA-4 is potentially capable of crosslinking
linking a single ligand, probably CD80, and forming complex network of interactions recep‐
tor:ligand interactions.
Along these similar lines, actual affinity of CTLA-4 for the B7 ligands is much higher than
with CD28. However, the differences between CD80 and CD86 binding to T-cell receptors
are less remarkable. Relative interaction properties of these molecules indicate preferential
interaction between CD80 and CTLA-4, whereas CD86 more biased towards CD28 [19, 20].
CD80 binds CTLA-4 with a modest 10-fold higher affinity than does CD86 ligand [19]. As
such, all other things being equal, when CD86 is expressed on APCs, then CD28 is more fa‐
vored interaction than CTLA-4 at the T-cell:APC interface. Thus, the activation signals elicit‐
ed by CD86:CD28 are less likely to be attenuated by coincident CTLA-4 ligation and
enhancing the costimulatory effects [19]. Actual preferences of each B7 molecule with CD28
and CTLA-4 were tested in APCs deficient in either CD86 or CD80, where relative seques‐
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tration of CD28 and CTLA-4 in the immunological synapse was evaluated. Results from this
study do indicate that CD80 does preferentially bind to CTLA-4 and CD86 shows better in‐
teraction with CD28 on the cell surface [26].
2.3. Functions of CD86/CD80:CD28/CTLA-4
As mentioned previously, the receptors CD28 and CTLA-4 are members of the CD28 family
of immunoglobulin-like glycoproteins expressed on both CD4+ and CD8+ T-cells. These re‐
ceptors share the same B7 ligands; however, they have opposing functions on T-cells. CD28
receptor activation supplies additional signals to support TCR-mediated responses, such as,
T-cell proliferation, cytokine production, cell survival, and promotes T-cell help to B cells [1,
27-29]. As expected, CD28 deficient mice have impaired T-cell activation in response to anti‐
gen [30], as well as, defective B cell responses [29, 31]. These additional costimulatory sig‐
nals provided by CD28 have been suggested to function to decrease the threshold for T-cell
activation, thereby, reducing the contact time with APC required for T-cell activation [32,
33]. CTLA-4 receptor activation provides signals to effectively attenuate T-cell responses.
The inhibitory function of CTLA-4 was first described from CTLA-4 deficient mice that ex‐
hibit a fatal CD4+ T-cell hyperproliferation and multi-organ infiltration [34-36]. These abnor‐
mally activated T-cells are potentially reactive to multiple self-antigens despite apparently
normal thymic selection [37]. These T-cells are primarily mediated through activation of
CD28, since mice deficient in both CTLA-4 and B7 do not develop disease [38, 39] and where
a specific mutation in CD28 prevents disease induction [40]. CTLA-4 has now been better
established in its role in the suppressive function of Treg cells [41-44]. The mechanisms by
which CTLA-4 in Treg cells directly suppresses immune responses includes the delivery of
negative signal towards inhibition of Teff cell proliferation and activation [45, 46], as well as,
through the removal of B7 molecules from the surface of the APCs [47]. However, there is
also the potential for CTLA-4 competition with CD28 for ligands that could contribute to
suppression functions as well. Altogether, CTLA-4 has a major role in modulating CD28-
mediated activation.
The differences in CD80 and CD86 function in regards to T-cell activation and inhibition are
not so well appreciated. There is still a general perception that CD80 and CD86 are inter‐
changeable costimulators with differences only in kinetics of expression and cell type distri‐
bution. Despite the obvious overlapping functions, these B7 molecules do show evidence of
distinct biological effects, predominantly with CD80 having more inhibitory roles and ef‐
fects on Treg cells. A classic example of this phenomenon is in the non-obese diabetic (NOD)
mouse model. In this model, blockade of CD80 by monoclonal antibodies (MAbs) exacer‐
bates disease, while blockade of CD86 prevents disease [48]. It is possible that with blocking
of CD86, the available CD80 could have enhanced interactions and would thus be free to in‐
teract with CTLA-4, thus attenuating T-cell activation. Blocking of CD80 would potentially
free CD86 to interact with CD28 making it more likely to provide help activate self-reactive
T-cells. Since NOD Tregs appear more dependent on CD80 for their maintenance, these self-
reactive T-cells may not be attenuated as well [49].
Genes and Autoimmunity - Intracellular Signaling and Microbiome Contribution102
A more recent regulatory function has also been found for CD80, where CD80 acts as an al‐
ternate ligand for programmed death ligand 1 (PD-L1, B7H1, CD274) [50]. PD-L1 is well
known to induce inhibitory signals in T-cells and to inhibit T cell proliferation. The affinity
of CD80 for PD-L1 is intermediate between its affinity for CD28 and CTLA-4, yet still three‐
fold less than the affinity of PD-L1 for PD-1 [50]. The function of this CD80:PD-L1 interac‐
tion in immune responses was shown in vivo where this pathway was shown to prevent
alloimmune responses and where these tolerogenic effects were mediated by the interac‐
tions of PD-L1 on APCs eliciting an inhibitory signal through CD80 expressed on T-cells
[51]. Specific blockade of this CD80/PD-L1 interaction indicates that the inhibitory signal
from CD80 but not PD-L1 is responsible for attenuation of T-cell expansion and enhance‐
ment of T-cell anergy. Blocking of this interaction specifically led to enhanced expansion
and restored antigen responsiveness in previously anergized T-cells [52].
2.3.1. Regulatory T cells
There are several lines of evidence suggesting that the expression of CD80 and CD86 ligands
by APCs are important in maintaining Treg cell homeostasis and suppressive function in the
periphery. B7 blockade experiments have indicated that continual expression of B7 in the
periphery is necessary to maintain the Treg compartment as indicated by the reduced CD25
expression following blockade [53]. Additionally, blocking antibodies to B7 also was capable
of inhibiting the natural turnover of adoptively transferred Treg cells in vivo [54].
The relative contribution of CD86 and CD80 to Treg cell responses is more difficult to de‐
scribe because of their overlapping functions, however, definite differences have been indi‐
cated. The relative expression levels of CD86 and CD80 on DCs are well known to be
modulated during the progression from immature to mature state. For example, DCs ex‐
pressing high levels of CD86, makes them particularly proficient at driving Treg cell prolif‐
eration [55], where CD86 was shown to be more important than CD80 in this regard [56].
These findings are all consistent with CD86 being a better ligand for CD28 in the face of
CTLA-4 expression and potentially better at stimulating Treg proliferation in these settings.
CD80 appears to contribute more to the inhibitory functions of Treg cells through its in‐
volvement with CTLA-4. For example, in the presence of antibodies to either CD80 or
CTLA-4, Treg suppression abilities were impaired when the CD25- responder T cells are not
exposed to the blocking antibodies [56]. Evidence also suggests that Teff cells from B7-defi‐
cient mice are resistant to suppression by wild type Tregs, where CD80 on Teff cells was
largely shown to be the dominant ligand for mediating suppression capabilities of Treg cells
[57]. This effect is potentially mediated by a CD80 cell-intrinsic negative signal into Teff cells
that helps facilitate suppression. The receptor for B7 that mediated this effect was not identi‐
fied, but due to the requirement for Treg cells it appears to be mediated by CTLA-4 [57].The
transfection of either CD80 or CD86 into Chinese hamster ovary cells (CHO), indicate CD80
could direct CTLA-4-mediated inhibition of resting human T cells through the activities of
CD25+CTLA-4+ Treg cells [43]. Additional to the effects of CD80 through CTLA-4, suppres‐
sive functions of CD80 have shown that the PD-L1/CD80 pathway also leads to promotion
of the in vivo expansion of donor natural Tregs in allogeneic recipients [58]. The proposed
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mechanism of action is that IFN-gamma upregulates tissue expression of the PD-L1 on
APCs and parenchymal cells. Expression of PD-L1 on those cells in normal tissues is
thought to be capable of interacting with CD80 expressed on Treg cells, promoting develop‐
ment and maintenance of Treg cells [58].
Therefore, it is possible that under a steady state condition, low CD80 and PD-L1 expressed
by immature DCs preferentially interacts with CTLA-4 and CD80 predominantly expressed
by Treg cells, thus, promoting Treg function and maintenance. However, specific mecha‐
nisms of controlling Treg cell maintenance and suppression functions through these signal‐
ing molecules are still areas requiring exploring. Following inflammatory stimuli and DC
maturation, where there is a relative upregulation of CD86 compared to CD80 along with
higher levels of antigenic stimulation, Treg suppressive capacity should become reduced.
This is supported by the finding that CD28 and TCR stimulation could antagonize suppres‐
sive function of Treg cells [43, 59]. Therefore, CD80 and CD86 may have somewhat oppos‐
ing roles in aiding suppressive capacity through CTLA-4 vs. activation of T-cells cells
through CD28, where their relative expression could influence this balance (Figure 1).
Figure 1. Mechanism by which Treg cells balance responses to B7 ligand stimulation. (A) Relatively high expression of
CD80 on APC favours enhancing suppressive function of Treg cell and inhibits T-cell proliferation. (B) Increase in CD86
following activation of APC favours inhibition of Treg cells and enhances T-cell proliferation. Specific signalling re‐
quirements of Treg activation and inactivation are still to be determined.
3. Impact of CD86/CD80 molecules in autoimmune disease
The relative contribution of CD86 and CD80 to the development of autoimmunity is difficult
to evaluate because of the diverse cells and interactions involved in disease pathogenesis.
However, interesting trends have appeared where alterations in relative expression of CD86
and CD80 in the target tissues and alterations in Treg numbers and function may contribute
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to the onset of autoimmune diseases. In this section we will review some information on the
rheumatic autoimmune diseases systemic lupus erythematosus and rheumatoid arthritis as
well as cover important findings regarding autoimmune diabetes. The major focus of this
section will be on elucidating the pathogenesis of Sjögren’s syndrome as it is related to tar‐
get tissue expression of B7 molecules and role of Treg cells in these tissues.
3.1. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic multi-organ autoimmune disease distin‐
guish by imbalanced T-cell  homeostasis towards activated Teff cell  subsets Th1 and Th2
and can affect  multiple  organs and systems of  the body.  It  is  well  characterized by the
number and variety of autoantibodies produced and is well marked by anti-nuclear anti‐
body production. Many of the symptoms are caused by impaired antigen-antibody com‐
plex  clearance  and thus  triggering inflammatory responses  in  multiple  sites.  Because  of
the difficulty in evaluating patient disease progression several  mouse models have been
used to  evaluate  how abnormal  costimulation and Treg cells  contribute  to  disease.  The
autoimmune  BXD2  mice  indicates  that  type  I  IFN  can  promote  autoimmune  responses
through  the  upregulation  of  CD86high  expression  on  marginal  zone  precursor  B-cells,
which  were  shown  to  be  located  at  the  T-B-cell  border  of  the  spleen  germinal  centers
[60].  In  regards  to  Treg  maintenance,  the  (NZB  x  NZW)F1  and  (SWR/NZB)F1  lupus-
prone mice had reduced numbers of CD4+CD25+ cells [61]. There was no intrinsic defect
in the suppressive function of the (NZB x NZW) F1 mice [62]. Additionally, only margin‐
al defects in Treg suppression were observed in MRL/Mp mice [63].  MRL/lpr mice with
strong  lupus  disease  were  found  to  have  normal  percentages  of  peripheral
CD4+CD25high T-cells and that Foxp3 expression was unaltered. However,  they do dis‐
play  a  reduced  capacity  to  suppress  and  effector  CD4+CD25-  T-cells  were  significantly
less susceptible to suppression. Importantly they also found that CD80/CD86 were under‐
expressed on Teff, APCs, and on Treg cells, suggesting that the reduction in these mole‐
cules could be contributing to the reduced abilities of Treg cells to suppress [64].
3.2. Rheumatoid arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by inflammation
of the joints and surrounding tissue including mononuclear cell infiltration of synovial tis‐
sue. Predominant lymphocytes present in rheumatoid synovium focal infiltrates are lym‐
phocytes (predominantly CD4+ T-cells with relatively few positive for CD25), macrophages,
and plasma B cells. The expression of CD86 was readily detectable in the synovium com‐
pared to osteoarthritis synovial [65]. In contrast, CD80 expression was not significantly ex‐
pressed in the synovium [65]. Overall, the expression of CD80 on APCs in the synovium is
generally low, while expression of CD86 is relatively high and is expressed on several APCs
including DCs, B-cells, and macrophages [66-70]. Blocking of CD28 signaling pathway has
also been shown to prevent or even treat autoimmune disease [71], indicating that CD28 is
probably a regulator in the induction of autoimmune diseases. For instance, CD28 deficient
mice are resistant to collagen induced arthritis [72] and inhibition of both CD80 and CD86
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during the induction phase of collagen induced arthritis prevents the development of dis‐
ease [71, 73, 74]. Arthritis is also abolished and autoantibody production is suppressed in
MLR/lpr mice lacking CD28, however, the accumulation of abnormal T cells is almost un‐
changed [75]. Indicating CD28 may have a better role in aiding B cell responses in this mod‐
el. Most importantly, treatment with blocking CTLA-4-Ig also significantly improved signs
and symptoms and Treg function of RA patients in clinical trials [76]. In general, Treg cells
with diminished suppressive capacity were obtained from synovial fluid of patients with
RA [77, 78]. Functional studies of Treg cell defects in mice related to RA indicate that defects
in CD4+Foxp3+ Treg cells in K/BxNsf mice exhibited earlier onset and more aggressive pro‐
gression of arthritis than K/BxN littermates [79]. This was accompanied by plasmacytoid
dendritic cells expressing high levels of CD86 and CD40, but not CD80, in synovia and in‐
crease memory CD4+ T-cells in the spleen and draining lymph nodes [79]. These mice also
exhibit an abnormal accumulation of mature plasma cells in spleen and associated loss of
bone marrow plasma cells. These plasma cells were also less susceptible to cell death [80].
Overall, it appears the function of CD28 to the pathogenesis of RA, potentially mediated
through over expression of CD86 appears to have a major function in disease pathogenesis.
3.3. Autoimmune diabetes
B7 molecules have potential influence on autoreactive T cells in animals genetically pre‐
disposed  to  autoimmune  disease.  Adoptive  transfer  of  NOD B-cells  previously  blocked
with B7 MAbs along with diabetogenic  T-cells  into NOD.scid mice protected associated
type  1  diabetes  [81].Again,  as  mentioned  previously  NOD  mice  treated  with  blocking
CD86 MAbs prevents the spontaneous development of diabetes,  whereas blocking CD80
accelerates  and worsened disease  [48].  Treatment  of  NOD mice  older  than 10  weeks  of
age with blocking CD86 MAbs did not alter the course of disease [48]. These results indi‐
cate that in the NOD background, the influence of CD86 to promotion and CD80 to sup‐
pression of disease occurs early on in disease pathogenesis. Breeding of CD86 deficiency
onto NOD background prevented the development of  diabetes,  as  expected from previ‐
ous studies. However, aging mice around age 20 weeks would develop a peripheral neu‐
ropathy characterized by demyelization and defective nerve function due to mononuclear
cell infiltration of peripheral nerves [82]. This was accompanied by a high level of CD80
expression on the APCs in the spleen as well  as on the nerves of  affected animals [82].
This is similar to reports seen in Experimental Autoimmune Epithelitis (EAE) and Multi‐
ple Sclerosis (MS) patients [83,  84],  where downregulation of CD86 and upregulation of
CD80 is  observed on CNS-infiltrating cells  and splenocytes.  These somewhat conflicting
findings for autoimmune diseases can potentially be explained by differences in interplay
of local  cellular  interactions,  cytokines and chemokines that  may alter  B7 expression.  In
this  case,  high expression of  CD80 could potentially  allow activation of  CD28 signaling
and autoimmune activation rather than suppression.
There is still some debate on whether Treg cells contribute to autoimmunity with regards to
their deficits and functionality in autoimmune diabetes. Treg depletion or B7-deficiency (sig‐
nificant loss in CD4+CD25+ cell population) in NOD mice leads to accelerated disease onset
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[53, 54]. The importance of Treg number to quality of suppression was shown with polyclo‐
nal Treg adoptive transfer to NOD.scid at a 2:1 ratio (Treg:Th1) was unable to suppress,
while 5:1 ratio was able to provide protection in approximately half of the recipients. There‐
fore, with sufficiently large populations of Tregs, there may be adequate numbers of anti‐
gen-specific Tregs capable of suppressing diabetes [85]. It is interesting to note that Treg
cells developed in vitro from induced GAD-IgG transduced splenocytes were capable of
suppressing diabetes in NOD mice. This was accompanied by a higher ratio of CD80 com‐
pared to CD86 expression in splenocytes, which was sufficient to allow development of
functional Treg cells (Foxp3+) in this model [86-88]. Depletion of CD4+CD25+ cells from
transduced splenocytes transferred into NOD mice showed increased ratio of CD86 to CD80
in splenocytes. Blocking of CD80, but not CD86, reduced the relative quantity of Foxp3 [87].
Along these lines, a progressive decrease was observed in the Treg cell:Teff cell ratio in in‐
flamed islets but not in pancreatic lymph nodes in NOD mice. Intra-islet Treg cells ex‐
pressed reduced amounts of CD25 and Bcl-2, where the administration of low-dose
interleukin-2 (IL-2) promoted Treg cell survival and protected mice from developing diabe‐
tes. Together, these results suggest intra-islet Treg cell dysfunction is a root cause of the pro‐
gressive breakdown of self-tolerance and the development of diabetes in nonobese diabetic
mice [89]. However, there is still some debate on whether NOD mouse Treg cells are suffi‐
cient in regulating Teff, since Tregs from NOD and B6g7 mice were equally effective but
NOD T conventional cells were hyper-responsive to stimulation [90].
3.4. Sjögren’s syndrome
Recently in SjS, as with some of the other autoimmune diseases previously mentioned, the
emphasis of pathogenicity has been placed on CD86 expression in the salivary gland envi‐
ronment. Expression of CD86 and CD80 in SjS patient salivary gland tissue compared to pa‐
tients with nonspecific sialadenitis was first described in 1999, where expression of both
ligands were found in ductal and acinar regions of immunohistochemically stained tissue
sections [91]. It was recently shown that the functional expression of CD86 on salivary gland
epithelial cells derived from SjS patients are capable of interacting with CD28, but its bind‐
ing to CTLA-4 was reduced [92]. Therefore, salivary epithelial cells are possibly functioning
to promote production of IL-2 and T-cell proliferation. This paper also indicates that expres‐
sion of CD80, contrary to other immunohistochemistry results suggesting that CD80 is ex‐
pressed [93],[94], could not be established in their salivary gland epithelial cells. It is difficult
to establish the relative expression of these molecules in vivo, since several other studies
were conducted on cell lines derived from patient biopsies under cytokine stimulating con‐
ditions or from immunohistochemistry of tissue sections using BB1 antibody, which poten‐
tially shares reactivity with non-B7 proteins such as MHC class II invariant chain [92, 95].
Further studies may be required to verify the production of CD80 as well as the relative ex‐
pression of each of these ligands in the salivary glands of patients and healthy controls.
However, in C57BL/6 (B6) mice the overall expression of B7 is relatively low (CD86 greater
than CD80) in normal mouse submandibular salivary glands compared to lymphoid tissues
and is located predominantly along the ducts and among acini as previously indicated in
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human patients (data unpublished, [96]). Presumably, these cells are salivary gland epithe‐
lial cells, where the expression of low level costimulatory ligands is presumed normal and
possibly protective. As for mouse models for SjS, retinoblastoma-associated protein 48
(RbAp48) transgenic mice, using a salivary gland specific promoter [97], resulted in the de‐
velopment of SjS-like symptoms. In salivary gland tissues of these mice the protein expres‐
sion of MHC class II, CD86, CD80, and ICAM-1 were all upregulated in affected mice
salivary glands. Where the expression levels of CD86 is higher than CD80 in the SMX, indi‐
cating a potential pathogenic role of CD86 to disease initiation [96]. Another mouse model
of SjS, the C57BL/6.NOD-Aec1Aec2 is a double congenic mouse model of primary SjS syn‐
drome that contains two genetic regions (Idd3 and Idd5) derived from the NOD mouse
model [98]. These genetic regions confer spontaneous development of SjS-like syndrome on
the B6 background. A recent study using this model highlighted the importance of local B7
molecules and signaling through CD28 to disease progression [99]. In this report AAV trans‐
duced expression of the CTLA-4-Ig (blocks B7 molecules interactions) in the salivary glands
of SjS-prone mouse model. Delivery of this gene construct via AAV prior to disease onset
prevented glandular damage and lymphocytic cell infiltration commonly associated with
disease, as well as, prevented loss of saliva secretion in the treated mice [99]. This was also
accompanied by a significant increase in transforming growth factor beta-1 (TGF-B1) in the
salivary glands and draining lymph nodes of these mice [99]. These results suggest a poten‐
tial regulatory role (either Treg or epithelial cells) involved with treatment of CTLA-4-Ig.
Authors of this paper did not explore the mechanisms of action of this molecule. Along simi‐
lar lines, another study involving treatment of blocking CD86 MAbs to another mouse mod‐
el of primary SjS, the NFS/sld 3-day thymectomized mutant, was shown to prevent the
autoimmune lesions and autoantibody production to a-fodrin [100]. Along with previous
lines of research indicating a negative regulatory role of CD80, no significant effects were
seen in mice treated with anti-CD80 MAbs [100]. These results together outline the impor‐
tance of costimulation to disease onset and severity and highlight the influence of CD86-
CD28 as a potential mediator of disease initiation in salivary and lacrimal glands.
Results regarding Treg involvement in the pathogenesis of SjS have been contradictory.
However, increasing evidence details defects in Treg contributing to disease. Recently it has
also been shown that in situ patrolling Tregs are essential for protection against autoim‐
mune exocrinopathy. In this system, CCR7 deficient mice were unable to allow Treg egress
from lymph nodes into peripheral tissues such as salivary and lacrimal glands, and that this
resulted in disease resembling SjS [101]. Interestingly, wild-type C57BL/6 mice evaluation
showed approximately 30% lacrimal and 23% salivary expression of Foxp3+ cells under
steady-state conditions, while CCR7-deficient mice had approximately 7% and 9% respec‐
tively [101]. The Foxp3-deficient scurfy mouse model (essentially deficient in Treg cells)
adds more complexity to the issue of roles of Tregs, since these mice do not develop inflam‐
mation or inflammatory cell infiltration into their salivary or lacrimal glands, however,
adoptive transfer to Rag-deficient mice induces multi-organ inflammation in salivary, lacri‐
mal glands, stomach, small intestine, pancreas, colon, and even skeletal muscle. This includ‐
ed inflammation in the lacrimal and salivary glands as well as inhibited salivary function,
where infiltration was located primarily in the acini and granular convoluted tubules [102].
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SjS patients have also been shown to have decreased number of Tregs (CCR7+Foxp3+) in
salivary glands compared to controls [101]. In line with this direct tissue evidence, there are
also several other reports of fewer salivary Tregs present in patients with SjS [103, 104] and
reports of Tregs with decreased suppression capabilities [105]. Reports of increased number
of Foxp3+ Treg cells in the salivary glands of patients with SjS [105, 106], was positively cor‐
related with the grade of infiltration as evaluated by Chisholm score [106]. The authors do
not address potential mechanisms for this observation. The observed number of Foxp3+ cells
in the peripheral blood was unchanging between SjS, RA, and healthy controls [106]. It is
possible that the observations of increased numbers of Treg cells in the salivary glands of
patients with SjS could be a result of proliferative enrichment due to increased costimulato‐
ry signaling (CD28 and CD86), and may have altered suppressive function as a result.
4. Conclusions
In autoimmune diseases, dysfunction of Treg cells is a potential contributor to disease devel‐
opment, where costimulatory requirements for Treg cell proliferation and suppression capa‐
bilities may not be met. Based on reviewed research on autoimmune diseases, it appears
that contribution of CD86 to Teff cells via CD28 signaling are potentially one of the initiating
factors of disease, at least in the cases RA, autoimmune diabetes, and SjS. The lack of CD80
regulatory effects on these diseases appears in general to be due to a lack of expression on
certain cell types, such as resident epithelium as in RA and SjS. In the previously mentioned
model where CD80 helps suppressive Treg function, this relative lack of CD80 earlier in dis‐
ease onset could be contributing to the allowance of autoreactive T-cells to respond towards
self-antigens. However, regulatory mechanisms of B7 ligand expression as well as the differ‐
ential signaling mechanisms that control Treg maintenance and function with regards to
CD80 and CTLA-4 signaling pathways have yet to be elucidated. Some of the previously
mentioned contradictory findings as to abnormal expression of B7 molecules and their func‐
tion in autoimmune diseases could be explained by multiple factors such as genetic back‐
ground, relative expression of B7 ligands, immune microenvironment, and timing of critical
immunological events. Better understanding costimulatory and inhibitory requirements of
CD80 and CD86 are worth further looking into since clinical trials involving CTLA-4-Ig
(Abatacept, Orencia) have shown promise in clinical improvement for RA [107] but not so
well in controlling flares in patients with non-life threatening SLE [108]. Clinical trials are
also underway for MS and Type I diabetes, where findings do show efficacy in controlling
disease activity in MS [109] and delaying beta cell loss in diabetes patients [110]. There is no
data available for use of CTLA-4-Ig in SjS patients. However, the previously mentioned
findings with CTLA-4-Ig in SjS-prone mice do show promise for the use of costimulatory
blockade in prevention of disease [99]. Mechanisms involving these observed protective ef‐
fects of blocking B7 with regards to Treg maintenance and function should also be explored,
since regulation of specific Treg populations may contribute to development of autoimmun‐
ity. Overall, there are still many questions as to how the CD86/CD80:CD28/CTLA-4 family
interacts to form specific immune responses in vivo, especially in the areas of Treg develop‐
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ment, homeostasis, and suppression function. It is well established that Treg cells are impor‐
tant to the prevention of autoimmunity. Whether targeting costimulatory molecules to drive
desirable Treg development and function to a complete reversal of disease phenotype needs
to be further clarified in autoimmune diseases, especially in SjS.
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